– Topline results presented at AUA 2018 evaluate clinical utility of 18F fluciclovine PET/CT imaging in men with recurrent prostate cancer following prior treatment – BURLINGTON, Mass. and OXFORD,...Read More ›
Welcome to Blue Earth Diagnostics
Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.